Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Gene Therapy of Type 1C Usher Syndrome using Mouse Models
EF 2019-20
Résumé
"Type 1C Usher Syndrome (USH-1C) is a genetic disorder that typically follows a recessive mendellian inheritance pattern, and is characterized by deafblindness and poor balance. It has its highest prevalence, and is the leading cause of deafblindness in French-Canadian and Acadian populations. Because of USH-1C's cosmopolitan rarity there are no human gene therapies as of November 24, 2019. There are however, mouse gene therapies for USH-1C, but they only focus on restoring hearing and vestibular function, and no therapy for vision restoration has been explored. The objective of the proposed research is to use USH-1C mouse models to begin development of potential gene therapies to restore vision, providing a foundation for USH-1C human vision-restorative gene therapy research in the future. This will help solve a public health issue that is endemic to Eastern Canadian populations, where no current treatment besides cochlear implants are available. This study will be an assessment of the effects and success of several gene therapeutic methods, such as adenoviral vectors, viral vectors, stem cells, and others, and use of gene drives such as CRISPR/Cas9. According to past research on related syndromes, it is thought lentiviruses will be most effective; however, finding non-lentiviral vectors would be preferable due to potential mutagenesis. Furthermore, this research can compare effects of gene addition as opposed to gene replacement in USH-1C mice, in order to predict which method would be optimal in humans. This study will contribute towards a Master's Thesis, and is expected to be finished within maximum of two academic years. "
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
428704
Name
Bauer William G
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Gene Therapy of Type 1C Usher Syndrome using Mouse Models
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acadian; Congenital; French-Canadian; Gene Therapy; Hearing; Medical Genetics; Mouse; Type 1c Usher Syndrome; Vectors; Vision
Abstract
"Type 1C Usher Syndrome (USH-1C) is a genetic disorder that typically follows a recessive mendellian inheritance pattern, and is characterized by deafblindness and poor balance. It has its highest prevalence, and is the leading cause of deafblindness in French-Canadian and Acadian populations. Because of USH-1C's cosmopolitan rarity there are no human gene therapies as of November 24, 2019. There are however, mouse gene therapies for USH-1C, but they only focus on restoring hearing and vestibular function, and no therapy for vision restoration has been explored. The objective of the proposed research is to use USH-1C mouse models to begin development of potential gene therapies to restore vision, providing a foundation for USH-1C human vision-restorative gene therapy research in the future. This will help solve a public health issue that is endemic to Eastern Canadian populations, where no current treatment besides cochlear implants are available. This study will be an assessment of the effects and success of several gene therapeutic methods, such as adenoviral vectors, viral vectors, stem cells, and others, and use of gene drives such as CRISPR/Cas9. According to past research on related syndromes, it is thought lentiviruses will be most effective; however, finding non-lentiviral vectors would be preferable due to potential mutagenesis. Furthermore, this research can compare effects of gene addition as opposed to gene replacement in USH-1C mice, in order to predict which method would be optimal in humans. This study will contribute towards a Master's Thesis, and is expected to be finished within maximum of two academic years. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bauer, William G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~